Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saginil Gel is a topically applied CE-marked medical device developed by Epitech Group for the symptomatic treatment of gynecological and vaginal inflammatory conditions. Its primary active ingredient is **adelmidrol**, a synthetic analogue of palmitoylethanolamide belonging to the ALIAmide (Autacoid Local Injury Antagonist Amide) class. The gel works by modulating the activity of local non-neuronal immune cells, particularly mast cells, to reduce inflammation, itching, burning, and pain. In addition to adelmidrol, the formulation contains sodium hyaluronate for hydration, phytosphingosine for barrier support, and quercetin for its antioxidant properties. It is specifically indicated for conditions such as vulvodynia, vulvar vestibulitis, and various forms of vaginitis, featuring bioadhesive properties to ensure prolonged local action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Saginil Gel.